

AREV LIFE SCIENCES GLOBAL CORP.  
PRESS RELEASE

**TEAM FROM QUEENSLAND BRAIN INSTITUTE IDENTIFIES NEW HERICERIN DERIVATIVES FROM LIONS MANE THAT BOOST NERVE GROWTH AND ENHANCES MEMORY**

VANCOUVER, BC / February 15, 2023 / AREV LIFE SCIENCES GLOBAL CORP. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation is pleased to announce it has commenced research to identify advanced isolation technology for its proprietary extract after learning results of a new study on *Heridium erinaceus* extract from Lions Mane.

Using super-resolution microscopy, the team from The Queensland Brain Institute - University of Queensland found the extract from Lions Mane Mushroom and its active components largely increase the size of growth cones, which are particularly important for brain cells to sense their environment and establish new connections with other neurons in the brain. N-de phenylethyl isohericerin (NDPIH), an isoindoline compound from this mushroom, together with its hydrophobic derivative hericene A, were highly potent in promoting extensive axon outgrowth and neurite branching in cultured hippocampal neurons even in the absence of serum, demonstrating potent neurotrophic activity.

The discovery has applications that could treat and protect against neurodegenerative cognitive disorders such as Alzheimer’s disease. Active compounds in the edible Lion’s Mane mushroom can help promote neurogenesis and enhance memory, the new study reports. Preclinical trials report the compound had a significant impact on neural growth and improved memory formation. Researchers say the compound could have clinical applications in treating and preventing neurodegenerative disorders such as Alzheimer’s disease. This new study was published in the *Journal of Neurochemistry* <https://onlinelibrary.wiley.com/doi/10.1111/jnc.15767> .

Arev’s Scientific Advisory Board Member Dr. Sateesh Apte, who specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences stated... “This is a very exciting finding. The neuroscience community is always trying to find pharmacologically active ingredients that would increase neuroplasticity in aging and degenerative conditions. Active ingredients such as NDPIH and Erinacene A, have shown remarkable promise in studies done in KU Leuven in Belgium and in Chung Shang University in Taiwan. It has been demonstrated that these compounds work much better in early stages of aging and neurodegeneration.”

In another study published in *Molecules*, the authors note, Ericenones could promote the secretion of nerve growth factor (NGF) in a rat adrenal medulla pheochromocytoma cell line (PC12). The erinacines were primarily separated from the *Heridium mycelium* fermented liquid, including erinacines A-K and erinacines P-R, and also had an effect in promoting the expression of NGF and the differentiation of axons in PC12 cells. Erinacines could induce relatively more NGF secretion than ericenones . The aqueous polysaccharide extract of *Heridium erinaceus* could promote peripheral nerve regeneration after a nerve injury crush in rats. The crude extracts of *Heridium erinaceus mycelium* inhibit purinoceptors to relieve neuropathic pain and neuro-inflammation in mice. (Source *Molecules* 2021, 26, 3297. <https://doi.org/10.3390/molecules26113297> )

This is an important discovery that supports the methods and technology AREV has developed. AREV continues to build on its core competency of extraction and formulation. Arev has successfully extracted 10% Hericenones using a modified method of its existing extraction technology. The 10% yield is exceptional, according to the expert mycologists working Arev’s Lions Mane extraction. With news of the discovery, the remaining 90% of the Arev extract which contains unidentified compounds that demonstrate polysaccharide characteristics needs to be isolated and identified. This requires additional processing with the ability to fractionalize our extracts

for medical and pharmaceutical compounding to treat specific diagnosis' and match custom oil blends to a patient's DNA sequencing thereby providing the optimal medical result available in the market.



250 grams Arev Lions Mane Extract

The company will now evaluate 3rd party isolation systems to separate targeted molecules from its Lions Mane extract and the other extracts from materials such as Full Spectrum Cannabis/Hemp Oil, Cinnamon, Frankinsence, Hops, and Moringa that Arev has also been working with. Ideally, the new technology will provide the versatility of compounding isolates for accurate micro-dosing which is ideal for pharmaceutical, bioceutical and nutraceutical applications.

Each "refinement" is being designed as a standard operating procedure "SOP" for the specific extraction of the natural substance that can ultimately be used as an active compound for an intended intervention to the particular health condition of the patient population.

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit [www.arevlifesciences.com](http://www.arevlifesciences.com).

On behalf of the Board,

Mike Withrow  
CEO & Director

### **About AREV Life Sciences Global Corp.**

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company's business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage.

AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTCanada and The Biotechnology Innovation Organization (BIO).

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**



## FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com).